The Dutch firm will incorporate Ibex Medical’s AI-based cancer diagnostics platform into its digital pathology solutions

Philips partners with Ibex Medical to globally commercialise AI-powered digital pathology solutions. (Credit: Koninklijke Philips N.V.)

Royal Philips has joined forces with Israel-based Ibex Medical Analytics for promoting their digital pathology and artificial intelligence (AI) solutions to hospitals, health networks, and pathology labs across the world.

The collaboration will see Philips combine its digital pathology solution – Philips IntelliSite Pathology with Ibex Medical’s AI-powered cancer diagnostics platform – Galen.

The combination is expected to provide objective, reproducible results, and boost diagnostic confidence. Besides, it will help in improving the productivity and efficiency that are required for handling the demand for pathology-based diagnostics.

Philips precision diagnosis chief business leader Kees Wesdorp said: “Building on our strong portfolio to support clinical decision-making in oncology, we bring together the power of imaging, pathology, genomics and longitudinal data with insights from artificial intelligence (AI) to help empower clinicians to deliver clear care pathways with predictable outcomes for every patient.

“By teaming with Ibex to incorporate their AI into our Digital Pathology Solutions, we’re further able to provide a continuous pathway, where critical patient data is made visible to both pathologists and oncologists to help improve the clinician experience and patient outcomes.”

Philips digital pathology solution is said to help fast track and simplify access to histopathology details across cancer care and beyond. It supports complete digitisation of histology in pathology labs and lab networks, and helps increase the efficiency of workflows.

The Philips IntelliSite Pathology solution features a pathology slide scanner, display, and an image management system. It includes advanced software tools for handling slide scanning, storage of images, reviews of cases, and the sharing of patient information.

On the other hand, the Galen platform from Ibex Medical provides AI-powered cancer detection, prioritisation of cases, grading, along with other insights for improving productivity.

The combination of the digital pathology solutions from Philips and the Galen platform is claimed to have enhanced efficiency in reporting by 27%. Furthermore, it has increased productivity by 37%, while improving consistency and accuracy to help with diagnostic confidence, said the partners.

Ibex Medical CEO and co-founder Joseph Mossel said: “Pathology is transforming at an increasing pace and AI is one of the major drivers, supporting a more rapid and accurate cancer diagnosis.

“By joining forces with Philips, the leader in digital pathology deployments, we can offer new end-to-end solutions enabling pathologists to implement integrated, AI-powered workflows across a broader segment of the diagnostic pathway, improving the quality of patient care and strengthening the business case for digitisation.”

The partnership with Philips follows a Series B funding round for Ibex Medical in which the company raised $38m. The funding round of the Israeli health technology start-up was led by Octopus Ventures and 83North.